Brain Hemorrhage Market

Market Overview:

The 7 major brain hemorrhage markets reached a value of US$ 136.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 211.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.03% during 2024-2034.

The brain hemorrhage market has been comprehensively analyzed in IMARC's new report titled "Brain Hemorrhage Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Brain hemorrhage refers to a potentially life-threatening medical condition in which bleeding occurs within the brain tissue or the surrounding membranes. This ailment can disrupt the normal functioning of the brain and cause various symptoms and complications. Individuals suffering from the illness may experience several neurological indications, such as severe headaches, sudden and extreme weakness or numbness in one side of the face or body, personality changes, confusion, disorientation, difficulty speaking or understanding speech, vision problems, loss of coordination or balance, seizures, etc. Various other signs may include nausea, vomiting, neck stiffness, changes in breathing patterns, etc. The diagnosis of brain hemorrhage typically requires a combination of clinical findings, medical history assessments, and numerous confirmatory studies. A healthcare provider will initially assess the patient's neurological function, including their level of consciousness, coordination, reflexes, sensory responses, etc., to help in determining the severity and location of the hemorrhage. Several other imaging tests, such as head computed tomography (CT) scans, brain magnetic resonance imaging (MRI), angiography, etc., are also used to obtain detailed cross-sectional pictures of the affected region.

The increasing cases of chronic high blood pressure, which can weaken the blood vessel walls over time, leading to brain ruptures and bleeding, are primarily driving the brain hemorrhage market. In addition to this, the rising incidence of several associated risk factors, such as drug abuse, traumatic brain injury, arteriovenous malformations, vascular abnormalities, use of blood-thinning medications, etc., is also propelling the market growth. Furthermore, the inflating adoption of effective drugs, including diuretics, antihypertensive agents, antiepileptics, etc., for reducing the disease symptoms is acting as another significant growth-inducing factor. Apart from this, the escalating application of endoscopic third ventriculostomy, which aims to restore the normal flow of cerebrospinal fluid and prevent the risk of infection and malfunction associated with other traditional surgeries, is also creating a positive outlook for the market. Moreover, the emerging popularity of stem cell therapy, owing to its various benefits, such as promoting tissue regeneration, enhancing recovery, modulating inflammatory response in patients, etc., is expected to drive the brain hemorrhage market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the brain hemorrhage market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for brain hemorrhage and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the brain hemorrhage market in any manner.

Recent Developments:

• In February 2024, Acasti Pharma Inc. reported that a poster summarizing its pivotal Phase 3 STRIVE-ON safety trial (NCT05995405) had been accepted for presentation at the 2024 International Stroke Conference. The STRIVE-ON trial is a prospective, open-label, randomized (1:1), parallel group trial of GTX-104 compared with oral nimodipine in patients hospitalized for aneurysmal subarachnoid hemorrhage.

Key Highlights:

• Acute, spontaneous intracerebral hemorrhage is the second-most prevalent type of stroke, affecting approximately 2 million people globally each year.
• Brain hemorrhage is more common among adults over age 65.
• Every year, roughly 12-15 per 100,000 people suffer from intracerebral hemorrhage, with 350 hypertensive hemorrhages per 100,000 senior people.
• Black and Hispanic people are more likely to experience intracerebral hemorrhage, particularly at a young age.
• Patients with a Glasgow Coma Scale (GCS) of less than 9 and a clot size of 60 ml or more have a nearly 90% death risk.

Drugs:

NYMALIZE, a dihydropyridine calcium channel blocker, improves neurological outcomes by reducing ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) caused by ruptured intracranial berry aneurysms, regardless of post-ictus neurological condition. The recommended oral dose is 10 mL (60 mg) every 4 hours for 21 days.

SFX-01 (Evgen Pharma) is a new agent that combines sulforaphane with α-cyclodextrin. The α-cyclodextrin ring forms a scaffold around sulforaphane, stabilizing it. Sulforaphane is released upon consumption, offering an effective technique of delivering sulforaphane clinically.

GTX-104 is a clinical stage injectable version of nimodipine that is being developed for intravenous infusion (IV) in aneurysmal subarachnoid hemorrhage patients to address major unmet medical needs. GTX-104's unique nanoparticle technology enables an aqueous formulation of insoluble nimodipine for standard peripheral IV infusion.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the brain hemorrhage market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the brain hemorrhage market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current brain hemorrhage marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the brain hemorrhage market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the brain hemorrhage market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the brain hemorrhage market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of brain hemorrhage across the seven major markets?
• What is the number of prevalent cases (2018-2034) of brain hemorrhage by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of brain hemorrhage by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with brain hemorrhage across the seven major markets?
• What is the size of the brain hemorrhage patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of brain hemorrhage?
• What will be the growth rate of patients across the seven major markets?
   

Brain Hemorrhage: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for brain hemorrhage drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the brain hemorrhage market?
• What are the key regulatory events related to the brain hemorrhage market?
• What is the structure of clinical trial landscape by status related to the brain hemorrhage market?
• What is the structure of clinical trial landscape by phase related to the brain hemorrhage market?
• What is the structure of clinical trial landscape by route of administration related to the brain hemorrhage market?